

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# **FOSUNPHARMA** **复星医药**

上海復星醫藥（集團）股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

## **CHANGE OF JOINT COMPANY SECRETARY**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Zhou Biao (“**Mr. Zhou**”) has ceased to be the joint company secretary of the Company (“**Joint Company Secretary**”) due to adjustment to work arrangement with effect from 27 June 2016.

Mr. Zhou confirmed that he had no disagreement with the Board and there were no other matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

The Board further announces that Ms. Dong Xiaoxian (董曉嫻) (“**Ms. Dong**”) has been appointed as a Joint Company Secretary with effect from 29 June 2016.

Ms. Dong, aged 35, is currently a Vice President and the secretary to the Board. Ms. Dong joined the Group in July 2003, where she has been worked as the secretary to the board of directors of Shanghai SIIC-SMU Biotech Co., Ltd. (上海實業醫大生物技術有限公司) from July 2003 to June 2006, and the Securities Affairs Assistant, Securities Affairs Representative, Deputy Director and Director of the Office of Board Secretary of the Company from July 2006 to June 2016. Ms. Dong graduated from Shanghai University (上海大學) with a Bachelor of Laws in 2003, and graduated with a Master of Business Administration Degree from Fudan University (復旦大學) in 2015.

Ms. Dong currently does not possess the specified qualifications as required under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Hong Kong Listing Rules**”), but Ms. Dong is knowledgeable and experienced in the operations of the Group. In this respect, the Company has applied for, and the Hong Kong Stock Exchange has granted a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Hong Kong Listing Rules in relation to Ms. Dong’s eligibility to act as a joint company secretary for a three-year period starting from 28 June 2016, on the condition that, among other things, Ms. Dong will be assisted by Ms. Lo Yee Har Susan (the current Joint Company Secretary) during the said period.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhou for his valuable contributions to the Company during his tenure of office as a Joint Company Secretary and to extend our warm welcome to Ms. Dong for her new appointment.

By order of the Board  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Chen Qiyu**  
*Chairman*

Shanghai, the PRC  
29 June 2016

*As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive Directors are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.*

*\* for identification purposes only*